RT Journal
A1 Romeo SG, Whalen RE, Tindall JP
T1 Intra-arterial administration of reserpine: Its use in patients with raynaud's disease or raynaud's phenomenon
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 1970
FD May 1
VO 125
IS 5
SP 825
OP 829
DO 10.1001/archinte.1970.00310050063006
UL http://dx.doi.org/10.1001/archinte.1970.00310050063006
AB Eighteen patients with either Raynaud's disease or Raynaud's phenomenon were given reserpine intra-arterially (1 mg) into one or both brachial arteries. Responses were graded 0 to 3+. Of the 12 patients with Raynaud's phenomenon, three showed a 3+ response, four showed a 2+ response, one showed a 1+ response, and four showed no response. Of the six patients with primary Raynaud's disease, three showed a 3+ response, none showed a 2+ response, one showed a 1+ response, and two showed no response. The average duration of clinical effectiveness was approximately seven months and side effects were minimal. Intraarterial administration of reserpine for Raynaud's disease and Raynaud's phenomenon deserves further clinical evaluation.